VISEN Pharmaceuticals Management
Management criteria checks 2/4
VISEN Pharmaceuticals' CEO is Pony Lu, appointed in Nov 2018, has a tenure of 6.5 years. total yearly compensation is CN¥28.66M, comprised of 13.6% salary and 86.4% bonuses, including company stock and options. directly owns 4.39% of the company’s shares, worth HK$220.25M. The average tenure of the management team and the board of directors is 4.1 years and 4.3 years respectively.
Key information
Pony Lu
Chief executive officer
CN¥18.0m
Total compensation
| CEO salary percentage | 17.65% |
| CEO tenure | 6.5yrs |
| CEO ownership | 4.4% |
| Management average tenure | 4.1yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CN¥171m |
| Dec 31 2023 | CN¥18m | CN¥3m | -CN¥250m |
| Dec 31 2022 | CN¥61m | CN¥2m | -CN¥289m |
Compensation vs Market: Pony's total compensation ($USD3.97M) is above average for companies of similar size in the Hong Kong market ($USD445.36K).
Compensation vs Earnings: Pony's compensation has increased whilst the company is unprofitable.
CEO
Pony Lu (56 yo)
Mr. An-bang Lu, also known as Pony, is Chief Executive Officer of VISEN Pharmaceuticals (Shanghai) Co., Ltd since November 07, 2018 and serves as its Executive Director since March 27, 2021 and served as i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 6.5yrs | CN¥17.99m | 4.39% HK$ 220.0m | |
| Chief Commercial Officer | 4.1yrs | no data | no data | |
| Company Secretary | less than a year | no data | no data |
Experienced Management: 2561's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 6.5yrs | CN¥17.99m | 4.39% HK$ 220.0m | |
| Non-Executive Director | 6.5yrs | no data | no data | |
| Chairman of the Board | 4.3yrs | no data | no data | |
| Independent Non-Executive Director | 4.1yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 4.1yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 4.1yrs | CN¥360.00k | no data | |
| Non-Executive Director | 6.5yrs | no data | no data | |
| Non-Executive Director | 1.4yrs | no data | no data | |
| Non-Executive Director | 4.3yrs | no data | no data |
Experienced Board: 2561's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 12:09 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
VISEN Pharmaceuticals is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chu Wang | Jefferies LLC |
| Po Han Lin | Morgan Stanley |